Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC–MS/MS method
Biomedical Chromatography · 2023-09 · 37 (9)
DOI: 10.1002/bmc.5689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 22.06.2023. Verfasst von Cesar P Bekegnran und 8 weiteren Autor:innen. Beteiligte Einrichtung: APHM, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, France. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre (BRC).
Abstract (Originalsprache)
Favipiravir, a broad‐spectrum RNA‐dependent RNA polymerase inhibitor, is currently being evaluated in preclinical and clinical studies for the treatment of various infectious diseases including COVID‐19. We developed an ultra‐performance liquid chromatography tandem mass spectrometry (UPLC–MS/MS) assay for the quantification of favipiravir and its hydroxide metabolite (M1), in human and hamster biological matrices. Analytes were separated on an Acquity UPLC HSS T3 column (2.1 × 100 mm, 1.8 μm) after a simple protein precipitation with acetonitrile. The mobile phase consisted of water and methanol, each containing 0.05% formic acid. Experiments were performed using electrospray ionization in the positive and negative ion mode, with protonated molecules used as the precursor ion and a total run time of 6 min. The MS/MS response was linear over the concentration ranges from 0.5–100 μg/ml for favipiravir and 0.25–30 μg/ml for M1. Intra‐ and inter‐day accuracy and precision were within the recommended limits of the European Medicines Agency guidelines. No significant matrix effect was observed, and the method was successfully applied to inform favipiravir dose adjustments in six immunocompromised children with severe RNA viral infections. In conclusion, the UPLC–MS/MS assay is suitable for quantification of favipiravir over a wide range of dosing regimens, and can easily be adapted to other matrices and species.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- APHM, Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, France.
- Unité des Virus Émergents (UVE: Aix-Marseille University-IRD 190-Inserm 1207), Marseille, France.
- UCL Great Ormond Street Institute of Child Health, London, UK.
- Department of Immunology and Gene Therapy, Great Ormond Street Hospital for Children NHS Trust Foundation, London, UK.
ORCID-Profile: Cesar P Bekegnran
Förderung
- National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre (BRC)
Zitieren
APA
Bekegnran, C. P., Driouich, J. S., Breuer, J., Barthelemy, K., Giocanti, M., de Lamballerie, X., Kreins, A. Y., Nougairede, A., & Solas, C. (2023). Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC–MS/MS method. Biomedical Chromatography, 37(9). https://doi.org/10.1002/bmc.5689
Vancouver
Bekegnran CP, Driouich JS, Breuer J, Barthelemy K, Giocanti M, de Lamballerie X, et al. Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC–MS/MS method. Biomedical Chromatography. 2023;37(9). doi:10.1002/bmc.5689
BibTeX
@article{Bekegnran2023,
author = {Bekegnran, Cesar P and Driouich, Jean-Selim and Breuer, Judith and Barthelemy, Karine and Giocanti, Madeleine and de Lamballerie, Xavier and Kreins, Alexandra Y and Nougairede, Antoine and Solas, Caroline},
title = {Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC–MS/MS method},
journal = {Biomedical Chromatography},
year = {2023},
volume = {37},
number = {9},
doi = {10.1002/bmc.5689}
}
EUVIMED